ArticlebioRxiv : the preprint server for biology2026
OpenGerminal: an open-source implementation of the Germinal antibody design pipeline.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Germinal is a recently described computational pipeline for de novo antibody design that combines AlphaFold-Multimer hallucination with antibody language model guidance to generate epitope-targeted antibodies. Germinal identified binders with nanomolar-to-low-micromolar affinities by testing only 43-101 designs per target across four diverse antigens, establishing it as a practical tool for epitope-directed antibody design accessible to standard academic laboratories. As this architecture is itself very recent, systematic replacement and benchmarking of its individual components remains largely unexplored, yet offers a valuable opportunity to probe the robustness of the underlying design. We present OpenGerminal, which replaces PyRosetta with a fully open-source stack comprising OpenMM 8.5.1, FreeSASA, FASPR, Biopython, and sc-rs v1.0.0, and adopts AbLang1 (ablang2 v0.2.1) as the sole antibody language model in place of IgLM. Benchmarking on two VHH targets (PD-L1 and IL-3) reveals that OpenGerminal achieves a markedly higher cofolding pass rate (PD-L1: 33.7% vs. 18.6%; IL-3: 24.6% vs. 8.0%) with equivalent or improved Chai-1 structural confidence metrics in accepted designs, at the cost of a modest increase in per-trajectory computation time (≥1.5×). Multi-chain target support is also extended and verified to run without error on the official insulin example. OpenGerminal provides the first systematic benchmarking of IgLM versus AbLang1 within the Germinal architecture, and its fully open-source component stack broadens the range of deployment contexts in which the pipeline can be used.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.